Big Pharmas like to give a push to aspiring research projects within their field. GSK is a key partner of the world’s largest life science startup accelerator, namely OneStart. Sanofi is engaged in new projects within diabetes research and also gives annual awards for scientists who have done outstanding medical research. Now, Boehringer Ingelheim joins the club to brace the search after cardiovascular medicines.
The new competitive research program is initiated by the European Society of Cardiology (ESC) and is called “ESC Grants for Medical Research Innovation”. With the support of Boehringer Ingelheim, four grants of up to €400,000 each will be awarded to research projects across the world.
“This grant project is a reflection of the ESC’s commitment to encouraging new and innovative research aimed at improving patient outcomes in thromboembolic disease – a leading cause of mortality worldwide,” said Professor Francesco Cosentino, the chair of the program’s scientific committee. It is estimated that one in four people die from causes related to thrombosis, such as atrial fibrillation, stroke or deep vein thrombosis. “More research into this disorder is urgently needed.”
Until 1 November 2015, projects around the world can apply, if they can posit a publishable outcome or data within 18 months. The 8 most promising applicants will then be invited to present and defend their proposals live to the Scientific Committee at the European Heart House in Nice.
For Boehringer Ingelheim, the competition captures new potential treatments for thromboembolic diseases, which is a key area in the company’s own pipeline. Cardiovascular diseases remain one of the biggest markets for biotech and pharma companies, and every competitive edge is needed.